Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8243681 | International Journal of Radiation Oncology*Biology*Physics | 2006 | 6 Pages |
Abstract
Conclusion: Preoperative concurrent capecitabine and concurrent protracted infusion 5-FU were both well tolerated, with similar, low rates of Grade 3-4 acute toxicity. No significant differences were seen in the pathologic response, local and distant recurrence, or overall survival among patients treated with preoperative RT and concurrent capecitabine compared with those treated with RT and concurrent protracted infusion 5-FU.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Prajnan M.D., M.S., M.P.H., Edward H. M.D., Sumita M.D., John M. M.D., Miguel A. M.D., Barry W. M.D., George J. M.D., Paulo M. M.D., Cathy M.D., Robert A. M.D., Marc E. M.D., Sunil M.D., Nora A. M.D., Christopher H. M.D.,